Central Core Disease

Central core disease is a rare, predominantly autosomal dominant congenital myopathy. It is caused most commonly by mutations in the RYR1 gene, encoding the skeletal muscle ryanodine receptor responsible for calcium release from the sarcoplasmic reticulum during excitation contraction coupling.

It produces a generally non progressive or slowly progressive proximal muscle weakness and hypotonia, typically presenting in infancy or early childhood.

It carries critical clinical importance because of its strong association with malignant hyperthermia susceptibility, reflecting the shared underlying ryanodine receptor abnormality. Specific anaesthetic precautions and family screening for this life threatening anaesthetic complication are an essential component of management for any affected individual and their relevant family members.

Pathophysiology

• Mutations in RYR1 disrupt normal ryanodine receptor function within the skeletal muscle sarcoplasmic reticulum, impairing calcium handling during muscle excitation contraction coupling.
• The resulting chronic mitochondrial and structural changes within affected muscle fibres produce the characteristic central, amorphous, oxidative enzyme deficient "core" regions visible on histological examination of muscle biopsy, from which the condition derives its name.
• The same ryanodine receptor abnormality that produces the chronic myopathic changes also predisposes affected individuals to malignant hyperthermia. This is a life threatening hypermetabolic reaction triggered by exposure to specific volatile anaesthetic agents and depolarising muscle relaxants (particularly succinylcholine).
• This shared pathophysiological link and genetic basis underlies the well established clinical association between the two conditions.

• The typical presentation is hypotonia and proximal muscle weakness, typically affecting the pelvic and shoulder girdle musculature. It presents in infancy with delayed motor milestones or, in milder cases, becomes apparent only in later childhood.
• The weakness is generally static or only very slowly progressive over subsequent years, in clear distinction from the more rapidly progressive course of several other myopathic conditions.
• Skeletal features, including congenital hip dislocation, scoliosis and other skeletal deformities, occur with increased frequency in affected individuals. They reflect the chronic effect of the underlying muscle weakness on normal skeletal development.
• Facial weakness and a characteristic myopathic facial appearance may be present, though generally milder than the limb girdle weakness.
• Respiratory muscle involvement is generally milder than in several other congenital myopathies but can occur in more severely affected individuals. Assess respiratory function where relevant clinical features are present.
• Specifically seek a family history of similar, generally mild and static, proximal weakness. Also seek a family history of a previous adverse anaesthetic event potentially consistent with malignant hyperthermia.
• This is critical given the autosomal dominant inheritance pattern of the condition and the relevance of the family history to anaesthetic risk assessment for the index patient and relevant family members.

• Muscle biopsy supports the diagnosis by demonstrating the characteristic central core histological appearance within type one predominant muscle fibres. The cores are well demarcated, central regions of reduced oxidative enzyme activity, most clearly visualised on specific histochemical staining.
• The histological pattern can show some variability and overlap with related congenital myopathies.
• Genetic testing for RYR1 mutations provides definitive diagnostic confirmation. It is increasingly the preferred initial diagnostic approach given the characteristic clinical presentation, and avoids the need for muscle biopsy in many cases where the clinical picture and family history are sufficiently characteristic.
• Genetic testing also provides essential information directly relevant to malignant hyperthermia risk assessment and family screening.
• Given the critical importance of the malignant hyperthermia association, any confirmed or strongly suspected diagnosis of central core disease should prompt consideration of formal malignant hyperthermia susceptibility testing. This is the caffeine halothane contracture test, performed on a fresh muscle biopsy sample at a specialised testing centre.
• Testing is indicated where genetic testing alone does not provide definitive reassurance about the mutation's malignant hyperthermia risk, or where the identified mutation has uncertain or established malignant hyperthermia association requiring confirmation.

• There is no specific disease modifying treatment for the underlying muscle weakness in central core disease. Management is predominantly supportive and rehabilitative, including physiotherapy to maintain strength and mobility.
• Orthopaedic assessment and management of associated skeletal deformity are needed. This includes scoliosis monitoring and, where indicated, surgical correction, and management of congenital hip dislocation according to standard orthopaedic principles.
• General supportive care addresses the functional consequences of the generally mild, static proximal weakness.
• The single most critical management consideration is full avoidance of malignant hyperthermia triggering anaesthetic agents (volatile inhalational anaesthetics and succinylcholine) in any affected or at risk individual.
• All affected patients, and their relevant family members, must be clearly identified as malignant hyperthermia susceptible. The autosomal dominant inheritance pattern confers a fifty percent risk to first degree relatives.
• Document this risk appropriately (a formal alert or warning system, medical alert jewellery or card), so that the information is available and acted upon at any future anaesthetic encounter.
• Use total intravenous anaesthesia with non triggering agents for any surgical or other procedure requiring anaesthesia in a confirmed or at risk individual. Avoid volatile agents and succinylcholine. Propofol based techniques and non depolarising muscle relaxants are standard safe alternatives.
• Dantrolene, the specific treatment for an established malignant hyperthermia crisis, must be immediately available in any setting where anaesthesia is administered to an affected or at risk patient.
• Family screening is an essential component of family centred management. It incorporates genetic testing of first degree relatives where the causative family mutation has been identified, with counselling on both the generally mild myopathic manifestations and, critically, the malignant hyperthermia risk and required anaesthetic precautions.
• This matters given the autosomal dominant inheritance and the potentially life threatening consequence of unrecognised malignant hyperthermia susceptibility in an affected family member undergoing anaesthesia without appropriate precautions.
• Regular clinical follow up includes monitoring for scoliosis progression and respiratory function assessment where clinically indicated, together with ongoing reinforcement of the essential anaesthetic precautions.
• This underpins long term management of this generally stable, though lifelong condition with its critical, specific anaesthetic risk implications.